TCW Group’s Haemonetics HAE Stock Holding History

TCW Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,184	Closed	-$457K	–	385
2017 Q3	$457K	Buy	+10,184	New	+$423K	﹤0.01%	354

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group's HAE Position: Q4 2017 in Review

TCW Group sold out of Haemonetics (HAE) in Q4 2017, closing a stake of 10,184 shares — an estimated $457K sold.

TCW Group first reported a position in HAE in Q3 2017 and held it in 1 quarter. The position peaked at $457K in Q3 2017. 246 funds tracked by Wall St. Rank hold HAE as of Q4 2017.

TCW Group reported no remaining Haemonetics position as of Q4 2017 after selling out during the quarter.
TCW Group sold 10,184 Haemonetics shares in Q4 2017, an estimated $457K.
TCW Group first reported a position in Haemonetics in Q3 2017 and held it in 1 quarter.
TCW Group's Haemonetics position peaked at $457K in Q3 2017.
246 funds tracked by Wall St. Rank held Haemonetics as of Q4 2017.

Based on TCW Group's 13F filing for Q4 2017, filed 9 Feb 2018.